Skip to main content
. 2023 May 18;60:102005. doi: 10.1016/j.eclinm.2023.102005

Table 3.

Weighted mean prices of typical chemotherapy doses in USD, standard pediatric patient (29 kg, BSA 1 m2).

Chemotherapy
WB income classification
WHO region
Name (Dosage form) Dose range HIC UMIC LLMIC AFRO AMR EMRO EURO SEARO WPRO
Asparaginase (IV) 6000 IU/m2 31.10 21.50 21.03 47.56 43.13 21.05 36.17 15.78 18.78
Bleomycin (IV) 5 mg/m2–15 mg/m2 5.02–15.06 3.83–11.48 5.52–16.55 7.46–22.37 9.74–29.22 6.33–18.99 2.66–7.98 5.83–17.48 10.44–31.31
Carboplatin (IV) 100 mg/m2–600 mg/m2 19.24–115.44 9.02–54.12 8.63–51.78 5.97–35.82 7.27–43.62 9.74–58.44 20.44–122.64 9.33–55.98 19.91–119.46
Cisplatin (IV) 20 mg/m2–100 mg/m2 7.67–38.35 1.89–9.46 1.38–6.90 3.04–15.19 4.00–20.01 0.32–1.61 3.88–19.38 1.29–6.44 6.22–31.10
Cyclophosphamide (IV) 250 mg/m2–2100 mg/m2 40.88–343.35 2.00–16.80 2.93–24.57 2.48–20.79 99.28–833.91 1.45–12.18 6.25–52.50 3.30–27.72 2.70–22.68
Cytarabine (IV) 50 mg/m2- 3000 mg/m2 1.35–81.00 1.45–87.00 0.65–39.00 1.00–59.70 0.55–32.70 0.79–47.10 1.32–79.20 1.06–63.30 2.03–121.80
Dacarbazine (IV) 375 mg/m2–800 mg/m2 28.76–61.36 24.64–52.56 19.91–42.48 48.30–103.04 22.95–48.96 15.83–33.76 19.43–41.44 38.59–82.32 49.09–104.72
Dactinomycin (IV) 45 mcg/kg 583.99 82.22 64.47 148.25 1632.56 247.56 120.71 13.57 77.00
Daunorubicin (IV) 20 mg/m2–60 mg/m2 37.02–111.07 4.17–12.52 7.72–23.15 14.36–43.09 69.97–209.91 8.51–25.52 18.56–55.67 7.47–22.40 7.89–23.66
Doxorubicin (IV) 20 mg/m2–75 mg/m2 12.12–45.47 6.84–25.65 8.61–32.28 5.24–19.67 6.22–23.34 6.15–23.07 11.37–42.65 11.10–41.63 14.25–53.45
Etoposide (IV) 75 mg/m2–200 mg/m2 9.45–25.20 2.18–5.80 2.63–7.00 6.83–18.20 5.27–14.04 4.06–10.82 7.54–20.10 3.14–8.38 5.67–15.12
Idarubicin (IV) 5 mg/m2–12 mg/m2 79.49–190.78 126.57–303.76 82.31–197.53 51.55–123.72 52.33–125.58 61.89–148.54 74.47–178.73 102.34–245.62 139.92–335.80
Ifosfamide (IV) 1800 mg/m2–5000 mg/m2 59.58–165.50 32.58–90.50 60.48–168.00 72.54–201.50 56.16–156.00 46.98–130.50 57.60–160.00 69.12–192.00 35.82–99.50
Mercaptopurine (tab) 50 mg/m2–75 mg/m2 1.55–2.33 0.49–0.74 0.22–0.33 2.77–4.16 1.30–1.94 0.59–0.88 1.96–2.93 0.20–0.29 1.04–1.55
Methotrexate (IV) 100 mg/m2–12000 mg/m2 8.64–1036.80 2.89–346.80 2.80–336.00 3.13–375.60 5.39–646.80 3.23–387.60 9.17–1100.40 2.64–316.80 6.36–763.20
Methotrexate (tab) 20 mg/m2 4.69 1.16 0.41 0.78 6.17 0.75 1.00 0.44 5.95
Pegaspargase (IV) 2500 IU/m2 3254.50 333.25 4384.75 1139.25 1166.00 313.00
Procarbazine (IV) 50 mg/m2–100 mg/m2 5.57–11.13 3.00–5.99 0.51–1.02 6.56–13.12 56.33–112.66 3.54–7.08 4.20–8.39 0.34–0.68 1.03–2.05
Rituximab (IV) 375 mg/m2 1737.68 867.26 650.03 756.19 2336.44 1138.05 1064.55 624.41 1186.76
Thiotepa (IV) 200 mg/m2–300 mg/m2 2766.46–4149.69 2435.14–3652.71 9055.38–13,583.07 1914.32–2871.48 707.28–1060.92
Thioguanine (tab) 30 mg/m2–100 mg/m2 5.72–19.05 2.40–8.01 0.37–1.23 4.44–14.79 10.06–33.54 1.67–5.55 4.81–16.03 0.54–1.80 4.16–13.88
Vinblastine (IV) 6 mg/m2 12.48 3.12 3.98 1.20 17.12 4.55 8.22 2.95 14.35
Vincristine (IV) 1 mg/m2–2 mg/m2 8.73–17.46 3.00–6.01 2.64–5.28 3.64–7.27 4.93–9.86 3.46–6.92 6.05–12.10 2.64–5.28 8.35–16.70

USD: United States dollars; WB: World Bank; WHO: World Health Organization; HIC: high income countries; UMIC: upper middle income countries; LLMIC: low and lower middle income countries; AFR: African Region; EMR: Eastern Mediterranean Region: EUR: European Region; AMR: Region of the Americas; SEAR: South-East Asian Region; WPR: Western Pacific Region; IV: intravenous; tab: tablet; IU: international unit; kg: kilogram; g: gram; mg: milligram; m: meter.

Source: This is based on internal analysis by Catherine Habashy, Tatenda Yemeke, Nancy Bolous, Yichen Chen, Sachiko Ozawa, Nickhill Bhakta, and Thomas Alexander using data from the following source: IQVIA MIDAS Quarterly Sales for the period 2012–2019 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.